Immusoft Corporation
Seattle, WA, US· latest recorded location
Immusoft Corporation is named on 4 US grants and 10 published applications in this corpus. Its most frequent classification is C12N (Microorganisms or enzymes).
- Granted patents
- 4
- Published applications
- 10
- Inventors
- 12
- Granted in 2026 so far
- 0
- Most recent grant
- 7 Jun 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Technology areas
Share of 14 documents
Recent patents
- Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors7 Jun 2022US 11,352,603 B2
- Method to achieve extended expression of DNA infused into liver31 Aug 2021US 11,103,582 B2
- Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors26 Mar 2019US 10,240,125 B2
- Vectors and methods for transducing B cells7 Jul 2015US 9,074,223 B2
- Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors31 Jul 2025US 2025/0243459 A1
- B cells for in vivo delivery of therapeutic agents16 Mar 2023US 2023/0081163 A1
- Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors19 Jan 2023US 2023/0013198 A1
- B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength18 Feb 2021US 2021/0047619 A1
- Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer21 May 2020US 2020/0157178 A1
Most cited
By later US patents